A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer’s bullish view on Abbott stock Copy link to section His Charitable Trust bought 275 shares of the medical devices company at $112 each on Monday. Cramer is confident that the weight-loss drugs are not a threat for this Chicago-based maker of FreeStyle Libre (continuous glucose monitoring system). The Mad Money host is bullish on Abbott stock also for the nutrition bus ...